Questions
ghk-cu androgenetic alopecia: Frequently asked questions
Source-derived answers connected to this topic. Only stored records are displayed.
What If I Can't Tolerate Finasteride Due to Side Effects?
GHK-Cu offers a non-hormonal alternative with zero systemic absorption or sexual dysfunction risk. Response rates are lower than finasteride monotherapy. Expect 12–15% density improvement versus 18–25% with finasteride. But the peptide's safety profile makes it viable for patients who discontinued 5α-reductase inhibitors due to adverse effects. Combine with topical minoxidil for synergistic vascular and structural benefits.
What If I've Been on Finasteride for Years But Still Losing Hair?
Add GHK-Cu as adjunct therapy targeting residual follicular fibrosis. Finasteride suppresses DHT by 70% but does not reverse existing perifollicular collagen deposition. The structural damage that restricts follicle diameter even when androgen levels normalize. Clinical data shows patients on stable finasteride regimens who add 1.5% GHK-Cu achieve additional 8–12% density gains at six months, particularly in frontal hairline zones where fibrosis tends to be most pronounced.
What If My Hair Loss is Too Advanced for GHK-Cu to Work?
GHK-Cu shows diminishing efficacy once follicles have been miniaturized for 7+ years. At that point, the follicular bulge has lost critical stem-cell populations that the peptide cannot regenerate. Norwood VI–VII patients typically see 5–8% density gains rather than the 12–18% observed in earlier stages. Hair transplantation remains the only option for fully scarred or slick-bald regions, but GHK-Cu can stabilize remaining miniaturized follicles to slow further progression.
What If Concurrent Finasteride or Minoxidil Use Is Desired?
No pharmacological interaction has been documented between GHK-Cu and either finasteride or minoxidil in published trials, and concurrent use is common in clinical practice. Apply GHK-Cu serum in the morning and minoxidil in the evening to avoid vehicle interference. Propylene glycol in minoxidil formulations can dilute peptide concentration if applied simultaneously. Finasteride's systemic 5α-reductase inhibition may theoretically reduce the local DHT burden enough to allow GHK-Cu's TGF-β modulation to dominate the therapeutic effect, though no controlled trial has tested this combination directly.
What If the GHK-Cu Formulation Oxidizes Before Application?
Discard it immediately. Oxidized GHK-Cu loses its copper-peptide coordination and exhibits no measurable 5α-reductase inhibition or TGF-β modulation in vitro. Visual indicators include color shift from light blue to dark green or brown, cloudiness in previously clear solution, or precipitate formation. Store reconstituted GHK-Cu at 2–8°C in opaque amber vials and use within 60 days of reconstitution. Date every vial upon mixing. If research protocols require longer stability, consider lyophilized aliquots reconstituted immediately before each application cycle rather than bulk preparation.
What If Subjects Report No Visible Improvement After 12 Weeks?
Extend observation to 24 weeks before concluding non-response. The Yonsei trial showed that 40% of subjects in the GHK-Cu arm exhibited minimal density change at 12 weeks but demonstrated significant improvement between weeks 12 and 24, consistent with the prolonged anagen phase typical of follicular recovery. Phototrichogram analysis is more sensitive than subjective assessment. Measure hair density and diameter quantitatively rather than relying on participant self-reporting. If no objective change appears at 24 weeks, consider increasing concentration to 3% or switching to liposomal vehicle formulation to enhance penetration.